



Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer

Gaoxiang Wang^{1,2†}, Xianning Wu^{1,2†}, Xiaohui Sun^{1,2}, Tian Li^{1,2}, Meiqing Xu^{1,2}, Liangdong Xu^{1,2} and Mingran Xie^{1,2*}

¹ Department of Thoracic Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China, ² Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

OPEN ACCESS

Edited by:

Pasquale Pisapia, University of Naples Federico II, Italy

Reviewed by:

Davide Franceschini, University of Milan, Italy Rocco Trisolini, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy

> *Correspondence: Mingran Xie xmr1981@ustc.edu.cn

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology

Received: 06 September 2020 Accepted: 16 November 2020 Published: 15 December 2020

Citation:

Wang G, Wu X, Sun X, Li T, Xu M, Xu L and Xie M (2020) Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer. Front. Oncol. 10:603378. doi: 10.3389/fonc.2020.603378 and prognosis of patients with pT1-3N0M0 non-small cell lung cancer (NSCLC). **Methods:** The cut-off value of the number of ELNs at the N1 station was obtained using X-tile software analysis. Kaplan-Meier survival curve analysis and the Cox proportional hazard model were used to study the impact of the number of ELNs at the N1 station on

Objective: This study aimed to analyze the relationship between the number of examined lymph nodes (ELNs) at the N1 station and the postoperative clinicopathological features

Results: The median survival time and 1-, 3- and 5-year survival rates of 0 ELNs at the N1 station were 28.0 months and 74.8%, 45.4%, and 21.2%, respectively. The median survival time and 1-, 3-, and 5-year survival rates of 1–4 ELNs at the N1 station were 45.0 months and 85.5%, 55.4%, and 39.1%, respectively. In the group with \geq 5 ELNs at the N1 station, the median survival time and the 1-, 3- and 5-year survival rates were 59.0 months and 94.0%, 62.7%, and 48.2%, respectively. Both univariate and multivariate Cox regression analyses showed that the number of ELNs at the N1 station, T stage and operation type were independent factors affecting the prognosis of patients with pT1-3N0M0 NSCLC.

Conclusion: Increasing the number of ELNs at the N1 station is positively correlated with the long-term survival rate of patients with T1-3N0M0 NSCLC. At least 5 LNs at the N1 station should be examined in pathological examination.

Keywords: examined lymph node, non-small cell lung cancer, survival, prognosis, surgery

the prognosis of postoperative patients with pT1-3N0M0 NSCLC.

INTRODUCTION

The morbidity and mortality of lung cancer are ranked first among all malignant tumors in the world (1, 2). The lung cancer histological types small cell lung cancer and non-small cell lung cancer (NSCLC) comprise 85% of all lung cancers, of which NSCLC accounts for 80% (1, 3). Radical resection remains the primary treatment for early resectable NSCLC. However, the postoperative 5-year survival rate is only 50% to 60% (4).

NSCLC patients with positive lymph nodes have a high risk of recurrence after surgery. Lymph node involvement is an important factor that determines the prognosis and treatment decision of postoperative NSCLC patients. Lymph node resection or sampling plays a crucial role in accurate lymph node staging. The results of lymph node pathological examination can determine the postoperative lymph node stage of the patient, determine the postoperative pathological stage of the patient, and guide the next step of treatment. Accurate postoperative staging is the key to determine whether patients should receive adjuvant therapy after surgery. Additionally, according to the International Association for Lung Cancer Research's lymph node map, the NCCN guidelines recommend that thoracic surgeons sample only one or more lymph nodes from mediastinal lymph node stations (2R, 4R, 7, 8 and 9 on the right; 4L, 5, 6, 7, 8 and 9 on the left) (5, 6).

Because lymph nodes at the N1 station (stations 10, 11, 12, 13 and 14) are located in the lungs, they are often not examined by surgeons and pathologists after surgery. Thus, postoperative pathological N1 stage is evaluated as N0, resulting in the lack of adjuvant treatment after an operation and increasing the risk of postoperative recurrence. Presently, many studies have reported on the number of examined lymph nodes (ELNs) in patients with resectable NSCLC (7–9), but few have focused on the minimum number of ELNs at the N1 station. Therefore, this study aimed to explore whether the number of ELNs at the N1 station affects the long-term survival of patients with pT1-3N0M0 NSCLC.

METHODS

Patient Selection

This study evaluated 1,510 NSCLC patients who had undergone radical resection of lung cancer at the affiliated Provincial Hospital of Anhui Medical University between January 2010 and April 2015. All the patients received lobectomy (or pneumonectomy) plus systematic hilar and mediastinal lymph node dissection. The inclusion criteria were as follows: 1) pathological diagnosis of NSCLC; 2) postoperative pathological stage of pT1-3N0M0; and 3) R0 resection. The exclusion criteria were as follows: 1) distant metastasis found during surgery or confirmed to be T4N1-2M1, 2) neoadjuvant therapy before surgery, and 3) incomplete medical records.

The clinical data were obtained from the LinkDoc database, supplemented by electronic medical record review. In this study, TNM staging, T staging, N staging and M staging were performed according to the 8th edition of the Lung Cancer Staging Project of the American Joint Commission on Cancer (AJCC). This study was approved by the Affiliated Provincial Hospital of Anhui Medical University.

Variables and Outcomes

This study collected and analyzed sex, age, smoking history, operation type, tumor location, tumor diameter, histology, tumor differentiation, T stage, preoperative complications and

postoperative chemotherapy in patients with T1-3N0M0 NSCLC. The primary endpoint was overall survival (OS), which was defined as the interval between the date of operation and date of death from any cause or the last follow-up. We surveyed the patients at 3-month intervals for the first 2 years and at 6-month intervals thereafter. The follow-up evaluations generally included a physical examination, blood analysis (including pertinent tumor markers), chest radiography, and chest CT. Whenever there were symptoms or signs indicative of recurrence, further evaluations, including CT of the abdomen, brain magnetic resonance imaging, positron emission tomography-CT or bone scintigraphy, were performed.

Statistical Analyses

The categorical and continuous variables between the groups were compared by χ 2-test and independent samples t-test as appropriate. The optimal number of ELNs at the N1 station was calculated using the X-tile model based on the maximum chi-squared value when a series of log-rank tests were conducted. Survival curves were depicted by the Kaplan-Meier method and compared among groups using the log-rank test. Multivariate Cox regression analyses were applied to identify the independent predictors for survival. Statistical analyses were conducted using SPSS Statistics (version 24; IBM, NY, USA). Differences with p < 0.05 were considered statistically significant.

RESULTS

Patient Characteristics

In total, 702 patients were included in this study. According to the relationship between the number of ELNs at the N1 station and OS in patients with pT1-3N0M0 NSCLC, the cohort was divided into three groups based on the X-tile model: 0 ELNs at the N1 station, 1–4 ELNs at the N1 station and \geq 5 ELNs at the N1 station. 0 ELNs at the N1 station were defined as Group A, 1–4 ELNs at the N1 station were defined as Group B, and \geq 5 ELNs at the N1 station were defined as Group C. The baseline characteristics are depicted in **Table 1**. The T stage had a significant influence on the number of ELNs at the N1 station. The results showed that the later was the T stage, the greater was the effect on the number of ELNs at the N1 station. Additionally, no significant difference was found in age, sex, smoking history, operation type, tumor location, tumor diameter, histology, tumor differentiation, preoperative complications or postoperative chemotherapy among the three groups.

In total, 9,608 lymph nodes were examined in the whole group, of which the number of ELNs at the N1 station was 2,849. The median number of ELNs was 13 (range: 0–35), and the median number of stations at which lymph nodes were examined was 3 (range: 0–8). The median number of ELNs at the N1 station was 3 (range: 0–20). The distribution of the number of ELNs at the N1 station in the NSCLC patients is shown in **Figure 1**.

Impact of the Number of Examined Lymph Nodes on Survival

The follow-up period was from January 2010 to April 2020, with a total follow-up period of 112 months. The median survival time and

TABLE 1 | Baseline characteristics of the study population.

	Group A (n = 152)	Group B (n = 281)	Group C (n = 269)	χ²	P Value
Sex				3.770	0.152
Male	110(72.4%)	185(65.8%)	196(72.9%)		
Female	42(27.6%)	96(34.2%)	73(27.1%)		
Age,years				0.427	0.808
≤ 60	69(45.4%)	133(47.3%)	131(48.7%)		
>60	83(54.6%)	148(52.7%)	138(51.3%)		
Smoking history		. ,	. ,	4.168	0.124
Yes	48(31.6%)	107(38.1%)	112(41.6%)		
No	104(68.4%)	174(61.9%)	157(58.4%)		
Operation type				2.566	0.277
Lobectomy	136(89.5%)	261(92.9%)	240(89.2%)		
Pneumonectomy	16(10.5%)	20(7.1%)	29(10.8%)		
Tumor location		. ,		11.942	0.154
RUL	46(30.3%)	68(24.2%)	66(24.5%)		
RML	13(8.6%)	30(10.7%)	17(6.3%)		
RLL	30(19.7%)	50(17.8%)	61(22.7%)		
LUL	42(27.6%)	87(31.0%)	67(24.9%)		
LLL	21(13.8%)	46(16.4%)	58(21.%)		
Tumor diameter, cm	× ,	× ,		2.412	0.299
≤3	63(41.4%)	96(34.2%)	103(37.3%)		
>3	89(58.6%)	185(65.8%)	166(62.7%)		
Histology	× ,			2.641	0.619
ADC	89(58.6%)	166(59.1%)	144(53.5%)		
SCC	52(34.2%)	100(35.6%)	108(40.1%)		
Other*	11(7.2%)	15(5.3%)	17(6.3%)		
Tumor differentiation	()	- ()	()	9.380	0.052
High	6(3.9%)	10(3.6%)	11(4.1%)		
Medium	41(27.0%)	114(40.6%)	108(40.1%)		
Low	105(69.1%)	157(55.9%)	150(55.8%)		
T stage				16.876	0.002
T1	40(26.3%)	96(34.2%)	53(19.7%)		
Τ2	71(46.7%)	120(42.7%)	152(56.5%)		
ТЗ	41(27.0%)	65(23.1%)	64(23.8%)		
Postoperative chemotherapy	()		- ()	2,570	0.277
Yes	35(9.9%)	16(5.7%)	20(7.4%)		
No	117(90.1%)	265(94.3%)	249(92.6%)		
Preoperative Complications*		((, . ,	1.864	0.394
Yes	58(38.2%)	96(34.2%)	85(31.6%)		
No	94(61.8%)	185(65.8%)	184(68.4%)		
	0 ((0 (0 / 0)				

RUL, right upper lung; RML, Right middle lung; RLL, Right lower lung; LUL, Left upper lung; LLL, Left lower lung; ADC, adenocarcinoma; SCC, squamous cell carcinoma. * Includes adenosquamous carcinoma, giant-cell carcinoma, sarcoma, and so forth. *Includes high blood pressure, diabetes, arrhythmia, and so forth.

1-, 3- and 5-year survival rates were 46.0 months and 86.6%, 56.1%, and 39.5%, respectively. The median survival time and 1-, 3- and 5-year survival rates of 0 ELNs at the N1 station were 28.0 months and 74.8%, 45.4%, and 21.2%, respectively. The median survival time and 1-, 3-, and 5-year survival rates of 1–4 ELNs at the N1 station were 45.0 months and 85.5%, 55.4%, and 39.1%, respectively. In the group with ≥ 5 ELNs at the N1 station, the median survival time and 1-, 3- and 5-year survival rates were 59.0 months and 94.0%, 62.7%, and 48.2%, respectively. The survival rate of the group with ≥ 5 ELNs at the N1 station and the group with 1–4 ELNs at the N1 station. These results were statistically significant (*p*<0.001). The details are shown in **Figure 2**.

Univariate analysis of the clinicopathological data showed that the operation type, histology, T stage and ELNs at the N1 station were significantly correlated with patient survival (p<0.05). The details are shown in **Table 2**. The clinicopathological data of the

patients were incorporated into the Cox model for multivariate analysis. The results showed that the operation type, T stage and ELNs at the N1 station were independent prognostic factors affecting patient survival (p<0.05). The details are shown in **Table 3**.

Impact of the Number of Examined Lymph Nodes on T Stage

In comparing the pathological data, we found a significant difference in T stage among the three groups. Therefore, all the patients were classified according to T stage to test whether the number of ELNs at the N1 station in this study was suitable for patients with different T stages of NSCLC. In patients with stage T1, stage T2 and stage T3 NSCLC, the survival rate of the group with \geq 5 ELNs at the N1 station was significantly better than that of the group with 0 ELNs at the N1 station and the group with 1–4 ELNs at the N1 station, with a statistically significant difference (**Figures 3A–C**).





TABLE 2 | The prognostic factors associated with overall survival of patients in groups A, B, and C by univariate analysis.

Sex Male 491 47.0 ± 3.590 41.5 Female 211 46.0 ± 5.318 45.5 Ageyears		Case	Median survival time (month) (95% CI)	5-year survival rate (%)	P Value	
Male 491 47.0 ± 0.500 41.5 Female 21 46.0 ± 6.318 35.5 Female 333 44.0 ± 4.806 37.5 560 339 49.0 ± 3.216 41.3 Smoking history 50 45.0 ± 5.471 30.2 Yes 267 45.0 ± 5.471 30.2 Operation type 50 45.0 ± 5.471 30.2 Umore location 10 45.0 ± 5.471 40.7 Presumenectomy 63 48.0 ± 2.515 40.7 Presumenectomy 63 48.0 ± 2.515 40.7 Presumenectomy 63 49.0 ± 4.900 37.0 RuL 16 54.0 ± 7.916 42.0 RuL 141 56.0 ± 5.012 44.7 LUL 125 47.0 ± 0.518 39.8 Torro diameter, cm 1 45.0 ± 5.051 46.1 So 4.60 45.0 ± 4.547 40.9 So 1.0 ± 2.924 40.9 45.0 ± 4.547 40.9	Sex				0.430	
Fende 211 460 ± 5.318 35.5 Age.years 333 44.0 ± 4.806 37.5 >60 333 49.0 ± 3.216 41.3 Smoking history 90 32.16 41.3 Yes 267 45.0 ± 5.5471 40.0 No 45 45.0 ± 5.5471 40.0 Operation type 90 450 ± 2.515 40.7 Pneumonectomy 65 29.0 ± 5.459 28.0 Tumor tocation 80 43.0 ± 4.900 37.0 RML 60 54.0 ± 7.916 42.0 UUL 160 43.0 ± 4.901 36.6 LUL 125 40.0 37.0 UUL 160 50.0 ± 6.013 42.0 UUL 126 40.0 ± 5.033 42.8 33 40 45.0 ± 3.347 45.0 ApC 50.0 ± 6.033 42.8 45.3 More diameter, cm 90 10.0 ± 5.432 45.3 Tumor differentiation 73 4	Male	491	47.0 ± 3.590	41.5		
<table-container>Ape,varaSelo33344.0 ± 4.80443.0>>0036949.0 ± 3.21641.3Smoking history45.0 ± 5.47140.0Yes6745.0 ± 5.47140.0No43.049.0 ± 2.76739.2Operation Appe48.0 ± 2.51540.7Iubectomy63748.0 ± 2.51540.7Preunonectomy0520.0 ± 5.49926.0Pumor location70.043.0 ± 4.090RML18043.0 ± 4.09037.0RML19642.0 ± 5.51936.6LLL19642.0 ± 5.51936.6LLL19642.0 ± 5.51936.6LLL12547.0 ± 4.14839.8Tumor diameter, cm340.0SC3951.0 ± 2.92440.6SCC2045.0 ± 3.34737.3Histolog31.0 ± 5.42342.7Tumor differentiation31.0 ± 5.423High2762.0 ± 5.63141.1Ta18954.0 ± 4.52544.7Ling14354.0 ± 4.52544.7Ta17035.0 ± 2.50528.0Locations**31.3No6147.0 ± 2.69740.1Ta17035.0 ± 2.50528.0Posperative chemotherapy31.3No6143.0 ± 6.76331.3No6143.0 ± 6.76331.3No6243.0</table-container>	Female	211	46.0 ± 5.318	35.5		
\$60 333 44.0 ± 4.006 37.5 >60 369 40.0 ± 3.06 41.3 Smoking history ************************************	Age,years				0.366	
>00 369 49.0 ± 3.216 41.3 Smoking history	≤ 60	333	44.0 ± 4.806	37.5		
Smoking historyJes267450 ± 5.47140.0No42549.0 ± 2.76739.2Operation typeUULobectomy6529.0 ± 5.45928.0Pneumonectomy6529.0 ± 5.45928.0Tumor locationU18043.0 ± 4.90037.0RML6054.0 ± 7.91642.0RLL14156.0 ± 5.01244.7LUL19642.0 ± 5.51936.6LLL19645.0 ± 6.03342.8Sa26250.0 ± 6.03442.8Sa26250.0 ± 6.03442.8Sa26331.0 ± 5.42322.7Mistory2740.940.9Other*4331.0 ± 5.42322.7High2762.0 ± 5.63531.5Modlum26347.0 ± 4.52238.3Low1243.0 ± 6.76331.3Vari13017035.0 ± 2.50528.6Properative complications*U14.1113Yas5143.0 ± 6.76331.3No6145.0 ± 6.50139.2No6345.0 ± 6.50139.2No6363.0 ± 6.763<	>60	369	49.0 ± 3.216	41.3		
Yes 267 45.0 \pm 5.471 40.0 No 435 49.0 \pm 2.767 39.2 Operation type	Smoking history				0.843	
No 436 49.0 ± 2.767 39.2 Operation type	Yes	267	45.0 ± 5.471	40.0		
Operation type 637 48.0 ± 2.515 40.7 Lobectomy 65 29.0 ± 5.459 28.0 Tumo location	No	435	49.0 ± 2.767	39.2		
Lobectomy 637 48.0 ± 2.515 40.7 Prenumonectomy 65 29.0 ± 5.459 28.0 Tumor location	Operation type				0.006	
Pheumonectomy65 29.0 ± 5.459 28.0 Tumo locationRUL180 43.0 ± 4.900 37.0 RML60 54.0 ± 7.916 42.0 RLL141 56.0 ± 5.012 44.7 LUL196 42.0 ± 5.519 36.6 LLL125 47.0 ± 4.148 39.8 Tumo diameter, cm 33.3 440 45.0 ± 3.347 37.3 SC262260 ± 5.033 42.8 3^3 440 45.0 ± 3.347 37.3 Histopy 40.2 45.0 ± 4.597 40.9 Other' 43.3 31.0 ± 5.423 22.7 Other' 43.3 31.0 ± 5.423 22.7 Umon differentiation 12.234 45.0 ± 4.597 40.9 Other' 43.3 31.0 ± 5.423 22.7 Tumo differentiation 12.234 45.0 ± 4.597 40.9 The S27 62.0 ± 5.639 51.5 Medium263 47.0 ± 5.223 44.7 Ta189 54.0 ± 5.255 44.7 Ta17.1189 54.0 ± 2.505 29.6 <th post="" post<="" td=""><td>Lobectomy</td><td>637</td><td>48.0 ± 2.515</td><td>40.7</td><td></td></th>	<td>Lobectomy</td> <td>637</td> <td>48.0 ± 2.515</td> <td>40.7</td> <td></td>	Lobectomy	637	48.0 ± 2.515	40.7	
Tumor location INO 3.0 ± 4.900 $3.7.0$ RML 60 $5.4.0 \pm 7.916$ 42.0 RLL 141 56.0 ± 5.012 44.7 LUL 196 42.0 ± 5.519 36.6 LLL 125 47.0 ± 4.148 39.8 Tumor diameter, cm \leq^3 460 5.033 42.8 >3 440 45.0 ± 3.347 37.3 Histology ACC 399 51.0 ± 2.924 40.6 $Other'$ 43 31.0 ± 5.423 22.7 U Molecular State	Pneumonectomy	65	29.0 ± 5.459	28.0		
RUL 180 43.0 ± 4.900 37.0 RML 60 54.0 ± 7.916 42.0 RUL 141 56.0 ± 5.012 44.7 LUL 196 42.0 ± 5.519 36.6 LUL 192 47.0 ± 4.148 39.8 Tumor diameter, cm $=$ $=$ $=$ ≤ 3.3 40.0 45.0 ± 3.347 37.3 Histology $=$ $=$ $=$ ADC 39.9 51.0 ± 2.924 40.6 SCC 260 45.0 ± 4.597 40.9 Other* 43.0 21.0 ± 5.423 27.7 Tumor differentiation $=$ $=$ $=$ High 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 412 45.0 ± 5.255 44.7 T1 189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.7 T2 43.0 ± 6.763 31.3 50.0 ± 2.505 29.6 <	Tumor location				0.134	
RML 60 54.0 ± 7.916 42.0 RLL 141 56.0 ± 5.012 44.7 LUL 196 42.0 ± 5.519 36.6 LLL 125 47.0 ± 4.148 39.8 Tumor diameter, em $=$ $=$ ≤ 3 262 50.0 ± 5.033 42.8 >3 400 45.0 ± 3.347 37.3 Histology $=$ $=$ ADC 399 51.0 ± 2.924 40.6 SCC 260 45.0 ± 4.597 40.9 Other* 43 10.5 ± 5.423 22.7 Tumor differentiation $=$ $=$ High 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 5.235 44.7 Low 412 45.0 ± 3.501 38.8 Tage $=$ $=$ $=$ T1 193 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3 170 35.0 ± 2.505 29.6 Pr	RUL	180	43.0 ± 4.900	37.0		
RLL 141 56.0 ± 5.012 44.7 LUL 196 42.0 ± 5.519 36.6 LUL 125 47.0 ± 4.148 39.8 Lunor diameter, cm	RML	60	54.0 ± 7.916	42.0		
LUL196 42.0 ± 5.519 36.6 LUL125 47.0 ± 4.148 36.6 Tumor diameter, on 3 262 60.0 ± 5.03 42.8 >3 40 45.0 ± 3.347 37.3 Histology 1 40.0 50.0 ± 2.924 40.6 SCC 260 45.0 ± 4.597 40.9 Other* 43 31.0 ± 5.423 22.7 Tumor differentiation 1 263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 Low 412 45.0 ± 4.064 38.8 T age 1 151 64.0 ± 5.235 44.7 T2 34.3 50.0 ± 3.781 41.1 T3 170 25.05 29.6 Postporative chemotherapy 1 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preserative complications* 1 30.2 ± 5.051 39.1 Postporative chemotherapy 1 $30.2 \pm 3.02 \pm 3.648$ 40.2 Preserative complications* 1 $45.0 \pm 3.02 \pm 3.648$ 40.2 ELNs at N1 station 2 28.0 ± 5.863 21.2 0 152 28.0 ± 5.863 21.2	RLL	141	56.0 ± 5.012	44.7		
LLL125 47.0 ± 4.148 39.8Turnor diameter, cm ≤ 3 262 50.0 ± 5.033 42.8 >3 400 45.0 ± 3.347 37.3 HistologyADC399 51.0 ± 2.924 40.6 SCC260 45.0 ± 4.597 40.9 Other*30 45.0 ± 5.433 22.7 Turnor differentiationHigh27 62.0 ± 5.639 51.5 Medium263 47.0 ± 4.522 38.3 Low263 47.0 ± 4.522 38.3 T stageTTTT1189 54.0 ± 5.235 44.7 T2343 50.0 ± 3.781 41.1 T330 50.0 ± 2.505 29.6 Postoper Time of the second se	LUL	196	42.0 ± 5.519	36.6		
Turor diameter, cm ≤ 3 262 6.0 ± 5.033 42.8 ≥ 3 40 45.0 ± 3.347 37.6 Histolog 399 51.0 ± 2.924 40.6 SCC 260 45.0 ± 4.597 40.9 Other* 260 45.0 ± 4.597 40.9 Other* 263 47.0 ± 5.423 22.7 Turor differentiation 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 263 47.0 ± 4.522 38.3 Low 263 47.0 ± 4.522 38.3 Low 263 50.0 ± 3.781 41.1 T2 343 50.0 ± 3.781 41.1 T3 20 51.0 ± 2.057 40.1 T2 433 50.0 ± 3.781 41.1 T3 0 651 43.0 ± 6.763 31.3 No 651 43.0 ± 6.763 31.3 No 651 45.0 ± 3.501 39.2 No 633 $53.0 \pm 3.$	LLL	125	47.0 ± 4.148	39.8		
≤ 3 262 50.0 ± 5.033 42.8 >3440 45.0 ± 3.347 37.3 HistologyADC 399 51.0 ± 2.924 40.6 SCC 260 45.0 ± 4.597 40.9 Other* 43 31.0 ± 5.423 22.7 Tumor differentiationHigh 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 T stageTT 170 36.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3 170 36.0 ± 2.505 29.6 Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 61 43.0 ± 3.501 39.2 No 463 53.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ElNs at N1 station 152 28.0 ± 5.863 21.2	Tumor diameter, cm				0.150	
>3440 45.0 ± 3.347 37.3 HistologyADC399 51.0 ± 2.924 40.6 SCC260 45.0 ± 4.597 40.9 Other*43 31.0 ± 5.423 22.7 Tumor differentiationHigh27 62.0 ± 5.639 51.5 Medium263 47.0 ± 4.522 38.3 Low412 45.0 ± 4.064 38.8 T stageT1189 54.0 ± 5.235 44.7 T2 34.3 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 61 47.0 ± 2.697 40.2 Preoperative complications*Yes 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 Ellis at N1 station 21.2 $1-4$ 281 45.0 ± 5.651 39.1	≤3	262	50.0 ± 5.033	42.8		
HistologyADC399 51.0 ± 2.924 40.6 SCC260 45.0 ± 4.597 40.9 Other*43 31.0 ± 5.439 20.7 Tumor differentiationHigh27 62.0 ± 5.639 51.5 Medium263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 T asgeTT1189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 39.2 No 651 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 Elsa tN1 station0 152 28.0 ± 5.8631 21.2	>3	440	45.0 ± 3.347	37.3		
ADC399 51.0 ± 2.924 40.6SOC260 45.0 ± 4.597 40.9Other*43 31.0 ± 5.423 22.7Turmor differentiationHigh27 62.0 ± 5.639 51.5 Medium263 47.0 ± 4.522 38.3Low412 45.0 ± 4.064 38.8T stageT1189 54.0 ± 5.235 44.7 T2343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Properative complications*Yes239 45.0 ± 3.501 39.2 No463 53.0 ± 3.648 40.2 ELNA tN1 station0152 28.0 ± 5.863 21.2 1-4281 45.0 ± 5.051 39.1	Histology				0.010	
SCC 260 45.0 ± 4.597 40.9 Other* 43 31.0 ± 5.423 22.7 Tumor differentiation u u High 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 412 40.64 38.8 T stage u u u T1 189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3 170 35.0 ± 2.505 29.6 Postoperative chemotherapy u u u Yes 51 43.0 ± 6.763 31.3 No 651 43.0 ± 6.763 31.3 No 651 43.0 ± 6.763 31.3 No 651 35.0 ± 3.501 39.2 No 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station u u u 21.2 1-4 281 45.0 ± 5.051 <td>ADC</td> <td>399</td> <td>51.0 ± 2.924</td> <td>40.6</td> <td></td>	ADC	399	51.0 ± 2.924	40.6		
Other* 43 31.0 ± 5.423 22.7 Tumor differentiation High 27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 T stage T1 189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3 170 36.0 ± 5.235 29.6 Postoperative chemotherapy Yes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preoperative complications* Yes 53 45.0 ± 3.501 39.2 No 63 30.0 ± 3.648 30.2 No 39.2 30.0 ± 3.648 39.1 High 261 45.0 ± 5.651 39.1	SCC	260	45.0 ± 4.597	40.9		
Tumor differentiationHigh27 62.0 ± 5.639 51.5 Medium263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 T stageT1189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes51 43.0 ± 6.763 31.3 No651 47.0 ± 2.697 40.1 Preoperative complications*Yes239 45.0 ± 3.501 39.2 No463 35.0 ± 3.648 40.2 Etwa N1 station0152 28.0 ± 5.863 21.2	Other*	43	31.0 ± 5.423	22.7		
High27 62.0 ± 5.639 51.5 Medium 263 47.0 ± 4.522 38.3 Low 412 45.0 ± 4.064 38.8 T stage TTT1189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 651 45.0 ± 3.501 39.2 Preservative complications*Yes 239 45.0 ± 3.501 39.2 No 263 35.0 ± 3.648 40.2 ELNs at N1 station 152 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	Tumor differentiation				0.546	
No263 47.0 ± 4.522 38.3Low412 45.0 ± 4.064 38.8T stageTT1189 54.0 ± 5.235 44.7 T2343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6Postoperative chemotherapyYes51 43.0 ± 6.763 31.3No651 47.0 ± 2.697 40.1 Preoperative complications* yes 239 45.0 ± 3.501 39.2No633 35.0 ± 3.648 49.2 U 14.1 14.1 14.1 T4 281 45.0 ± 5.863 21.2	High	27	62.0 ± 5.639	51.5		
Low 412 45.0 ± 4.064 38.8 T stage	Medium	263	47.0 ± 4.522	38.3		
T stage 1 189 54.0 ± 5.235 44.7 T2 343 50.0 ± 3.781 41.1 T3 170 35.0 ± 2.505 29.6 Postoperative chemotherapy Yes 51 43.0 ± 6.763 31.3 No 651 43.0 ± 2.697 40.1 Presperative complications* Yes 239 45.0 ± 3.501 39.2 No 239 53.0 ± 3.648 30.2 Presterative complications* 39.2 30.0 ± 3.648 30.2 No 239 45.0 ± 3.501 39.2 No 30.2 30.0 ± 3.648 30.2 No 239 53.0 ± 3.648 30.2 No 230 30.0 ± 5.863 30.2 No 35.0 ± 5.863 21.2 39.1	Low	412	45.0 ± 4.064	38.8		
T1189 54.0 ± 5.235 44.7 T2343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes51 43.0 ± 6.763 31.3 No651 47.0 ± 2.697 40.1 Preoperative complications*Yes239 45.0 ± 3.501 39.2 No230 35.0 ± 3.648 49.2 ELNs at N1 station U U U 0152 28.0 ± 5.863 21.2 1-4281 45.0 ± 5.051 39.1	T stage				0.008	
T2343 50.0 ± 3.781 41.1 T3170 35.0 ± 2.505 29.6 Postoperative chemotherapyYes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preoperative complications*Yes 239 45.0 ± 3.501 39.2 No 239 35.0 ± 3.648 40.2 ELNs at N1 station0 152 28.0 ± 5.863 21.2 1-4281 45.0 ± 5.051 39.1	T1	189	54.0 ± 5.235	44.7		
T3 170 35.0 ± 2.505 29.6 Postoperative chemotherapy Yes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preoperative complications* 7 93.0 ± 3.501 39.2 Yes 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station 0 152 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	T2	343	50.0 ± 3.781	41.1		
Postoperative chemotherapy Ves 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preoperative complications* 7 9 39.2 No 630 53.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station 0 152 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	Т3	170	35.0 ± 2.505	29.6		
Yes 51 43.0 ± 6.763 31.3 No 651 47.0 ± 2.697 40.1 Preoperative complications* 7 9 39.2 Yes 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station 7 9 1.2 0 152 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	Postoperative chemotherapy				0.510	
No 651 47.0 ± 2.697 40.1 Preoperative complications* 40.1 Yes 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station 21.2 21.2 1-4 281 45.0 ± 5.051 39.1	Yes	51	43.0 ± 6.763	31.3		
Preoperative complications* Viscon 1 State <	No	651	47.0 + 2.697	40.1		
Yes 239 45.0 ± 3.501 39.2 No 463 53.0 ± 3.648 40.2 ELNs at N1 station 2 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	Preoperative complications*				0.676	
No 463 53.0 ± 3.648 40.2 ELNs at N1 station 2 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	Yes	239	45.0 ± 3.501	39.2		
ELNs at N1 station 28.0 ± 5.863 21.2 1-4 281 45.0 ± 5.051 39.1	No	463	53.0 ± 3.648	40.2		
0 152 28.0 ± 5.863 21.2 1-4 281 45.0 + 5.051 39.1	ELNs at N1 station			-	<0.001	
1-4 281 45.0 + 5.051 39.1	0	152	28.0 ± 5.863	21.2		
	1-4	281	45.0 ± 5.051	39.1		
>5 269 59.0 + 4.772 48.2	≥5	269	59.0 ± 4.772	48.2		

RUL, right upper lung; RML, right middle lung; RLL, right lower lung; LUL, left upper lung; LLL, left lower lung; ADC, adenocarcinoma; SCC, squamous cell carcinoma. *Includes adenosquamous carcinoma, giant-cell carcinoma, sarcoma, and so forth. ELNs, examined lymph node. *Includes high blood pressure, diabetes, arrhythmia, and so forth.

TABLE 3 | The prognostic factors associated with overall survival of patients in groups A, B, and C by multivariate Cox regression.

	P Value	RR (95% CI)
ELNs at N1 station	<0.001	0.638(0.562–0.725)
Operation type	0.025	1.429(1.046-1.951)
T stage	0.032	1.166(1.013-1.341)
Sex	0.186	-
Age	0.264	-
Smoking history	0.939	-
Tumor location	0.961	-
Tumor diameter	0.463	-
Histology	0.483	-
Tumor differentiation	0.497	-
Postoperative chemotherapy	0.792	-
Preoperative complications*	0.413	-

ELNs, examined lymph nodes. *Includes high blood pressure, diabetes, arrhythmia, and so forth.

DISCUSSION

The problem of postoperative recurrence in patients with NSCLC has always been a major issue faced by clinicians. The NCCN guidelines suggest that inadequate examination of lymph nodes reduces survival and recommend a minimum number of ELNs. For many cancers, such as gastric and breast cancer, the relationship between more lymph node detection and improved long-term survival has been well studied (10, 11). Additionally, studies have shown that insufficient detection of lymph nodes will increase the risk of recurrence in patients with NSCLC. However, few studies have investigated whether the number of ELNs at the N1 station affects the prognosis of patients with NSCLC (12-14). An accurate examination of lymph nodes has important reference significance for the postoperative pathological staging and prognosis evaluation of patients with NSCLC. In this study, the number of ELNs at the N1 station was significantly correlated with the long-term survival rate of pT1-3N0M0 NSCLC patients. The survival rate of patients with ≥ 5 ELNs at the N1 station was higher than that of the other two groups. Additionally, the survival rate of patients with 1–4 ELNs at the N1 station was higher than that of patients with 0 ELNs at the N1 station.

In this study, pT1-3N0M0 NSCLC patients who had undergone radical resection of lung cancer were divided into groups according to the number of ELNs at the N1 station. Through survival and multivariate analyses, we found that the long-term survival rate of pT1-3N0M0 NSCLC patients with ≥ 5 ELNs at the N1 station was higher than that of patients with 1-4 ELNs at the N1 station and patients with 0 ELNs at the N1 station, and the number of ELNs at the N1 station was an independent prognostic factor. Through analyses of the Chinese registry and Surveillance, Epidemiology, and End Results (SEER) database, Liang et al. found that a greater number of ELNs was related to more accurate lymph node staging and the long-term prognosis of NSCLC patients after surgery (15). Additionally, Liang et al. suggested that 16 lymph nodes should be examined as the best cut-off point for postoperative lymph node examination or prognosis stratification in N0 patients (15). Saynak M et al., by evaluating stage Ia NSCLC patients who had undergone lung



survival curves of groups A, B and C in T3 stage.

cancer surgery, found that the local recurrence rate of patients with N1 station lymph nodes examined was 14%, while the recurrence rate of patients without N1 station lymph nodes examined was 31%, suggesting that insufficient examination of N1 station lymph nodes cannot accurately determine the patient's pathological stage, resulting in insufficient postoperative adjuvant therapy (16).

We believe that the most important findings from this study are as follows. First, when the number of ELNs at the N1 station is low, the probability of positive hilar and intrapulmonary lymph nodes will be reduced, resulting in some postoperative NSCLC patients being mistakenly classified as N0 and in lower chances of postoperative adjuvant therapy and a worse prognosis. When more lymph node examinations are performed at the N1 station, the postoperative lymph node staging of NSCLC patients is more accurate, the chance of receiving adjuvant therapy is increased, and the prognosis is better. Such differences could explain the different survival times among the three groups. This phenomenon is considered the main reason for the results of this study. Second, the first site of lymph node metastasis in patients with NSCLC is the lymph nodes at the N1 station, and the examination of additional pathological sections of lymph nodes at the N1 station will increase the chance of lymph node micrometastasis at the N1 station being detected by pathologists. Thus, patients with stage N0 NSCLC can be accurately classified as stage N1, thus receiving adjuvant therapy postoperation to prolong survival.

In this study, NSCLC patients were refined according to T stage. Survival analysis showed that, in stages T1, T2 and T3, the longterm survival rate of patients with more than 5 ELNs at the N1 station was higher than that of patients with 1-4 ELNs at the N1 station and of patients with 0 ELNs at the N1 station. According to the results of this study, for patients with stage T1 to T3 NSCLC, thoracic surgeons should examine 5 or more N1 lymph nodes during the operation so that patients can obtain good and accurate postoperative pathological staging and sufficient postoperative adjuvant therapy to improve their prognosis. Additionally, through univariate and multivariate Cox regression, we found that the operation type is an independent prognostic factor for the prognosis of patients with pT1-3N0M0 NSCLC. We believe there are several reasons for this finding. First, 637 patients had undergone lobectomy, accounting for 90.7% of the whole population, whereas the percentage of patients who had undergone pneumonectomy accounted for 9.3%. Therefore, there was a certain statistical deviation. Second, most of the patients who had undergone pneumonectomy had central lung cancer, although they were pT1-3N0M0 patients, but the pathological stage was "later" than that of peripheral lung cancer, their survival time was generally short, and their prognosis was poor. Finally, patients who undergo pneumonectomy are more likely to develop respiratory failure, heart failure and other multiple organ failure than those who undergo lobectomy, thus affecting the prognosis.

Our study has several limitations. The main limitations are the retrospective nature of the analysis and nonrandomization, which may have resulted in potential selection bias. Another limitation is that it is difficult to separate each lymph node in the dissected tissue, leading to varying numbers of ELNs due to the fragmentation of lymph node tissue in the process of lymph node resection and possibly affecting the best cut-off point of the number of ELNs.

CONCLUSIONS

In patients with pT1-3N0M0 NSCLC, the long-term survival rate of those with \geq 5 ELNs at the N1 station was higher than that of patients with 1–4 ELNs at the N1 station and with 0 ELNs at the N1 station, and the number of ELNs at the N1 station was an independent prognostic factor. T stage and surgical method were identified as independent prognostic factors in patients with pT1-3N0M0 NSCLC. Considering some of the limitations of this study, a large cohort, multicenter and prospective study is needed to confirm our findings.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Affiliated Provincial Hospital of Anhui Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

GXW conceptualized the study, contributed to the methodology, provided the software, contributed to the investigation of the study, wrote the original draft, and wrote, reviewed, and edited the manuscript. XNW wrote the original draft, and wrote, reviewed, and edited the manuscript. XHS and TL contributed to the visualization and investigation of the study. MQX and LDX provided the software Software and contributed to the validation of the study. MRX acquired funding, and wrote, reviewed, and edited the manuscript. All authors contributed to the article andapproved the submitted version.

FUNDING

This work was supported by the grants from the National Natural Science Foundation of China, The Fundamental Research Funds for the Central Universities and Key research and development projects in Anhui Province (Nos. 81973643, WK9110000021, and 202004j07020017).

ACKNOWLEDGMENTS

The authors thank Linkdoc for her help with the regulatory management, data collection, and preparation of figures.

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3322/caac.21551
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi: 10.3322/caac.21338
- Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* (2010) 19:1893–907. doi: 10.1158/1055-9965.EPI-10-0437
- Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forth-coming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol* (2007) 2:706–14. doi: 10.1097/JTO.0b013e31812f3c1a
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer, V.3. (2020). Available at: https://www. nccn.org/professionals/physician_gls/pdf/nscl.pdf.
- Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, et al. The IASLC lung cancer staging project: A proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 4:568–77. doi: 10.1097/JTO.0b013e3181a0d82e
- Yendamuri S, Dhillon SS, Groman A, Dy G, Dexter E, Picone A, et al. Effect of the number of lymph nodes examined on the survival of patients with stage I non-small cell lung cancer who undergo sublobar resection. *J Thorac Cardiovasc Surg* (2018) 156:394–402. doi: 10.1016/j.jtcvs.2018.03.113
- Chen Y, Zhang J, Chen L, Dai J, Hu J, Zhu X, et al. Lymph Node Examination for Stage I Second Primary Lung Cancer Patients Who Received Second Surgical Treatment. *Ann Surg Oncol* (2020). doi: 10.1245/s10434-020-08975-9
- Ding H, Wang H, Xu L, Song N, Jiang G. Survival and Resected Lymph Node Number During Sublobar Resection for N0 Non-Small Cell Lung Cancer 2 cm or Less. Ann Thorac Surg (2019) 107:1647–55. doi: 10.1016/j.athoracsur. 2018.12.024
- National Comprehensive Cancer Network:. NCCN clinical practice guidelines in oncology: Gastric cancer, V.2. (2020). Available at: https://www.nccn.org/ professionals/physician_gls/pdf/gastric.pdf.

- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer, V.4. (2020). Available at: https://www.nccn.org/ professionals/physician_gls/pdf/breast.pdf.
- Wang X, Yan S, Lv C, Wang Y, Wang J, Li S, et al. Impact of Omission of Intrapulmonary Lymph Node Retrieval on Outcome Evaluation of Lung Cancer Patients Without Lymph Node Metastasis: A Propensity Score Matching Analysis. *Clin Lung Cancer* (2017) 18(6):e411–6.4. doi: 10.1016/ j.cllc.2017.05.001
- Ramirez RA, Wang CG, Miller LE, Adair CA, Berry A, Yu X, et al. Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer. *J Clin Oncol* (2012) 30(23):2823–8. doi: 10.1200/ JCO.2011.39.2589
- Eichhorn F, Klotz LV, Muley T, Kobinger S, Winter H, Eichhorn ME, et al. Prognostic relevance of regional lymph-node distribution in patients with N1positive non-small cell lung cancer: A retrospective single-center analysis. *Lung Cancer* (2019) 138:95–101. doi: 10.1016/j.lungcan.2019.10.018
- Liang W, He J, Shen Y, Shen J, He Q, Zhang J, et al. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol (2017) 35(11):1162– 70. doi: 10.1200/JCO.2016.67.5140
- Saynak M, Hubbs J, Nam J, Marks LB, Feins RH, Haithcock BE, et al. Variability in defining T1N0 non-small cell lung cancer impacts locoregional failure and survival. *Ann Thorac Surg* (2010) 90(5):1645–9, 1649-50. doi: 10.1016/j.athoracsur.2010.06.033

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Wu, Sun, Li, Xu, Xu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.